Abstract
The value of an inflammation-based prognostic score (GPS) was compared with performance status (ECOG) in patients (n=109) receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer. On multivariate analysis with ECOG, white cell count and the GPS entered as covariates, only the GPS was a significant independent predictor of survival (HR 1.88, 95% CI 1.25-2.84, P=0.002).
MeSH terms
-
Adult
-
Antineoplastic Agents / therapeutic use*
-
Biomarkers, Tumor / blood*
-
C-Reactive Protein / analysis
-
Carcinoma, Non-Small-Cell Lung / drug therapy
-
Carcinoma, Non-Small-Cell Lung / mortality*
-
Carcinoma, Non-Small-Cell Lung / pathology
-
Female
-
Humans
-
Hypoalbuminemia / blood
-
Inflammation / blood*
-
Inflammation / pathology
-
Lung Neoplasms / drug therapy
-
Lung Neoplasms / mortality*
-
Lung Neoplasms / pathology
-
Male
-
Middle Aged
-
Platinum Compounds / therapeutic use*
-
Prognosis
-
Survival Analysis
Substances
-
Antineoplastic Agents
-
Biomarkers, Tumor
-
Platinum Compounds
-
C-Reactive Protein